US drugmaker Pfizer announced that its experimental vaccine to prevent COVID-19, called BNT162b2, was 90 percent effective, according to initial data from a phase 3 study.
This is the first successful data from a large-scale clinical study of a coronavirus vaccine.
“Today is a great day for science and humanity. The first set of results from our Phase 3 COVID-19 vaccine trial provides initial evidence of our vaccine's ability to prevent it, ”said Albert Bourla, President and CEO of Pfizer.
"This is a victory for innovation, science and a global collaborative effort," added Ugur Sahin, co-founder and CEO of BioNTech.
Pfizer and its German partner, BioNTech, stated that they had not encountered serious safety issues, so they expect to apply for the US emergency use authorization by ...